US 12,435,097 B2
Arginase inhibitors and methods of use thereof
Scott Nathan Mlynarski, Waltham, MA (US); Tyler Grebe, Waltham, MA (US); Sameer Kawatkar, Waltham, MA (US); Maurice Raymond Verschoyle Finlay, Cambridge (GB); and Iain Simpson, Cambridge (GB)
Assigned to AstraZeneca AB, Sodertalje (SE)
Appl. No. 17/429,011
Filed by AstraZeneca AB, Sodertalje (SE)
PCT Filed Feb. 7, 2020, PCT No. PCT/IB2020/050982
§ 371(c)(1), (2) Date Aug. 6, 2021,
PCT Pub. No. WO2020/161675, PCT Pub. Date Aug. 13, 2020.
Claims priority of provisional application 62/802,765, filed on Feb. 8, 2019.
Prior Publication US 2022/0106335 A1, Apr. 7, 2022
Int. Cl. C07F 5/02 (2006.01)
CPC C07F 5/025 (2013.01) 15 Claims
 
1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein
R1 is —H or —C(O)CH(R1a)NHR1b; and
R1a is selected from —H, —(C1-C6) alkyl and CH2OR1c;
R1b is —H; or alternatively, R1a and R1b, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and
R1c is H or —CH3.